We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed at $74.17 in the latest trading session, marking a -1.92% move from the prior day. This change lagged the S&P 500's 1.44% loss on the day. Meanwhile, the Dow lost 1.27%, and the Nasdaq, a tech-heavy index, lost 2.06%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 2.36% over the past month. This has outpaced the Medical sector's loss of 2.15% and the S&P 500's loss of 2.61% in that time.
GILD will be looking to display strength as it nears its next earnings release, which is expected to be October 25, 2018. In that report, analysts expect GILD to post earnings of $1.66 per share. This would mark a year-over-year decline of 26.87%. Our most recent consensus estimate is calling for quarterly revenue of $5.43 billion, down 16.63% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.63 per share and revenue of $21.64 billion, which would represent changes of -25% and -17.09%, respectively, from the prior year.
Any recent changes to analyst estimates for GILD should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. GILD is currently a Zacks Rank #1 (Strong Buy).
Digging into valuation, GILD currently has a Forward P/E ratio of 11.4. For comparison, its industry has an average Forward P/E of 27.55, which means GILD is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 90, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
Gilead Sciences (GILD - Free Report) closed at $74.17 in the latest trading session, marking a -1.92% move from the prior day. This change lagged the S&P 500's 1.44% loss on the day. Meanwhile, the Dow lost 1.27%, and the Nasdaq, a tech-heavy index, lost 2.06%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 2.36% over the past month. This has outpaced the Medical sector's loss of 2.15% and the S&P 500's loss of 2.61% in that time.
GILD will be looking to display strength as it nears its next earnings release, which is expected to be October 25, 2018. In that report, analysts expect GILD to post earnings of $1.66 per share. This would mark a year-over-year decline of 26.87%. Our most recent consensus estimate is calling for quarterly revenue of $5.43 billion, down 16.63% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.63 per share and revenue of $21.64 billion, which would represent changes of -25% and -17.09%, respectively, from the prior year.
Any recent changes to analyst estimates for GILD should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. GILD is currently a Zacks Rank #1 (Strong Buy).
Digging into valuation, GILD currently has a Forward P/E ratio of 11.4. For comparison, its industry has an average Forward P/E of 27.55, which means GILD is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 90, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.